New scan could sharpen prostate cancer detection

NCT ID NCT07164027

Recruiting now Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early trial is testing whether a special PET/CT scan using flotufolastat F-18 can better guide prostate biopsies than standard MRI. The study will enroll 30 men with suspicious MRI findings. Researchers will compare how often the new method detects aggressive prostate cancer versus the usual approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F-18 (a radioactive tracer used in PET/CT scans)
What this could lead to: If successful, this imaging method could help doctors find aggressive prostate cancers more accurately, reducing unnecessary biopsies and improving treatment decisions.
What could go wrong: This is a very early (Phase 1) study with only 30 men, so results may not apply to everyone. The new scan might not prove better than current MRI-guided biopsy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.